AQST logo

AQST
Aquestive Therapeutics Inc

11,814
Mkt Cap
$730.68M
Volume
2.82M
52W High
$7.55
52W Low
$2.12
PE Ratio
-8.59
AQST Fundamentals
Price
$6.04
Prev Close
$6.13
Open
$6.41
50D MA
$5.88
Beta
1.37
Avg. Volume
2.98M
EPS (Annual)
-$0.5089
P/B
-178.86
Rev/Employee
$405,359.16
Loading...
Loading...
News
all
press releases
Aquestive Therapeutics (NASDAQ:AQST) Upgraded to "Hold" at Wall Street Zen
Wall Street Zen raised Aquestive Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Aquestive Therapeutics (NASDAQ:AQST) Releases Earnings Results
Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) released its earnings results on Wednesday. The company reported ($0.14) earnings per share for the quarter, missing analysts' consensus...
MarketBeat·3d ago
News Placeholder
Here's What Key Metrics Tell Us About Aquestive Therapeutics (AQST) Q3 Earnings
Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks·3d ago
News Placeholder
Aquestive Therapeutics (AQST) Reports Q3 Loss, Lags Revenue Estimates
Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -7.69% and -4.13%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Is DBV Technologies (DBVT) Stock Outpacing Its Medical Peers This Year?
Here is how DBV Technologies S.A. (DBVT) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.
Zacks·9d ago
News Placeholder
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
Here is how Aquestive Therapeutics (AQST) and Arcturus Therapeutics (ARCT) have performed compared to their sector so far this year.
Zacks·25d ago
News Placeholder
Aquestive Therapeutics (AQST) Surges 7.9%: Is This an Indication of Further Gains?
Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Zacks·30d ago
News Placeholder
Aquestive Stock Jumps After-Hours As CEO Sees $1B ‘Blockbuster’ Potential For Oral Allergy Film — Retail Sees Stock As Buyout Candidate
Aquestive’s Anaphylm has drawn heightened investor attention after the CEO spotlighted it as the company’s first broad-market product.
Stocktwits·1mo ago
News Placeholder
Aquestive Therapeutics (AQST) Soars 14.8%: Is Further Upside Left in the Stock?
Aquestive Therapeutics (AQST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Zacks·2mo ago
News Placeholder
AQST Stock Up as FDA Skips Advisory Meeting to Discuss Anaphylm NDA
Aquestive Therapeutics shares surge after FDA skips advisory meeting on Anaphylm NDA, keeping its January 2026 action date intact.
Zacks·2mo ago

Latest AQST News

View

Advertisement|Remove ads.

Advertisement|Remove ads.